-transparent.png){kind=logo}
From January 1976 to December 1979, 23 adults with advanced soft tissue sarcomas were treated with palliative chemotherapy associating cyclophosphamide, vincristine, adriamycin and dacarbazine (CYVADIC) according to two different schema administered successively. A higher than 50 per cent rate of tumoral response was observed in 52 per cent of cases with 13 per cent complete remissions. Median survival was 14 months in patients who responded to treatment, and 4 months in non-responders (p less than 0,01). Side effects were severe however, and it was necessary to discontinue treatment in 5 patients, and modify dosage in 9 other patients. The CYVADIC protocol is effective but requires some modifications to improve tolerance.
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
April 1995,
Seminars in oncology,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
January 1982,
European journal of cancer & clinical oncology,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
January 1980,
Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
January 1980,
Cancer treatment reports,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
March 2009,
Gan to kagaku ryoho. Cancer & chemotherapy,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
August 1997,
Hinyokika kiyo. Acta urologica Japonica,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
January 1980,
Chirurgisches Forum fur experimentelle und klinische Forschung,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
November 1985,
Klinische Wochenschrift,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
January 1986,
Cancer chemotherapy and pharmacology,
B Bui, and
J Chauvergne, and
M Durand, and
R Brunet
February 1996,
American journal of clinical oncology,
